Mark Cuban’s Cost Plus Drugs plans to enter custom rare-disease drug market

Mark Cuban says his company Cost Plus Drugs will expand beyond generic medicines into the custom‑made rare disease space. The firm, which currently buys generic drugs and sells them directly to consumers at a modest markup, sees an opportunity to reshape how specialty therapies are sourced.

Cuban’s plan represents a significant shift for a business that has built its brand on low‑cost, transparent pricing. By moving into rare‑disease medicines, Cost Plus Drugs hopes to apply its direct‑to‑consumer model to a market traditionally dominated by specialty pharmacies and pharmacy benefit managers.

The move is described as a bold swing for the company, aiming to improve access and affordability for patients with rare conditions while navigating the complexities of custom drug manufacturing.